World Journal of
Pharmaceutical and Life Sciences

INVITRO EVALUATION OF ISONIAZID AND ITS DERIVATIVE (PYRUVIC ACID CALCIUM ISONIAZID) FOR THE TREATMENT OF TUBERCULOSIS

Dr. Syed Ahmed Hussain* and Saniya Begum

ABSTRACT

Aim: To investigate the cytotoxic and anti-angiogenic effects of Pyruvic acid calcium isoniazid on HT-29 colorectal TB cells and HUVEC endothelial cells. Objective: To evaluate the impact of Pyruvic acid calcium isoniazid on cell proliferation, tube formation, and protein expression levels using MTT, Tubulogenesis, Indirect Immunofluorescence, and Western Blot assays. Research: The study employed various in vitro assays to assess the cytotoxicity and anti-angiogenic properties of Pyruvic acid calcium isoniazid. The MTT assay was used to determine cell viability, while the Tubulogenesis assay measured its effects on tube formation in HUVEC cells. The Indirect Immunofluorescence assay quantified the expression of NF-κB and VEGF-A in HT-29 cells and VEGFR-2 in HUVEC cells. Western Blot analysis was conducted to validate protein expression levels in treated cells. The results demonstrated a significant reduction in cell viability, tubulogenesis, and protein expression, indicating the compound's potential as an anti TB agent. Conclusion: Pyruvic acid calcium isoniazid showed significant cytotoxic and anti-angiogenic activity by reducing cell proliferation and inhibiting tube formation. It also downregulated the expression of key proteins involved in TB progression. The findings suggest that Pyruvic acid calcium isoniazid may be a promising candidate for further exploration as an antiTB therapy.

[Full Text Article]   [Download Certificate]